565.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$568.26
Aprire:
$565
Volume 24 ore:
339.44K
Relative Volume:
0.14
Capitalizzazione di mercato:
$210.30B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
31.07
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
+7.68%
1M Prestazione:
+10.45%
6M Prestazione:
-9.18%
1 anno Prestazione:
+18.46%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific Inc
|
565.89 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
192.76 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
559.01 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
138.42 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
260.00 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Piper Sandler Adjusts Price Target on Thermo Fisher Scientific to $600 From $510, Maintains Neutral Rating - marketscreener.com
Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 - Yahoo Finance Singapore
Thermo Fisher stock holds on steady earnings base - Ad-hoc-news.de
Thermo Fisher Scientific (NYSE:TMO) Faces A Margin Test - Kalkine Media
Thermo Fisher Scientific Q2 up 10% to USD 11.99 billion - Medical Buyer
Thermo Fisher stock trades steadily as diagnostics and biopharma demand support earnings trajectory - AD HOC NEWS
Thermo Fisher Scientific Inc. (TMO) Leads with RSI of 73 Amid Ea - GuruFocus
Thermo Fisher Scientific Inc. Revenue Breakdown – BX:TN8 - TradingView
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools BetsDanaher (NY - Benzinga
Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing - 01net
Thermo Fisher posts strong Q2 2026 with 10% rev... - Pluang
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Company News for July 24, 2026 - Yahoo Finance
Deutsche Bank Adjusts Thermo Fisher Scientific Price Target to $635 From $630, Maintains Buy Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Thermo Fisher Scientific to $660 From $615, Maintains Overweight Rating - marketscreener.com
Rothschild & Co Redburn Raises Price Target on Thermo Fisher Scientific to $625 From $610, Maintains Buy Rating - marketscreener.com
Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call - TIKR.com
RBC Raises Price Target on Thermo Fisher Scientific to $580 From $490, Keeps Sector Perform Rating - marketscreener.com
Barclays Adjusts Thermo Fisher Scientific Price Target to $650 From $625, Maintains Overweight Rating - marketscreener.com
Thermo Fisher raises 2026 outlook after 10% growth in Q2 - Yahoo Finance
Bernstein Adjusts PT on Thermo Fisher Scientific to $575 From $520, Maintains Market Perform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Thermo Fisher Scientific to $650 From $570, Maintains Buy Rating - marketscreener.com
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role - Yahoo Finance
Thermo Fisher stock holds steady ahead of earnings - Ad-hoc-news.de
THERMO FISHER SCIENTIFIC INC : LEERINK PARTNERS RAISES TARGET PRICE TO $620 FROM $600 - Bitget
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades - Yahoo! Finance Canada
Thermo Fisher Scientific Q2 Earnings Call Highlights - Yahoo Finance
TMO Q2 FY2026 earnings call - finance.biggo.com
Is It Too Late to Buy Thermo Fisher Scientific Inc (TMO) After 8 - GuruFocus
THERMO FISHER SCIENTIFIC INC : EVERCORE ISI RAISES TARGET PRICE TO $615 FROM $570 - Bitget
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $606.79, Implies 15% Upside - TradingView
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $630 From $585, Maintains Buy Rating - Moomoo
Thermo Fisher Scientific Inc.'s stock price skyrockets to $572.32, marking an impressive 8.71% surge - Smartkarma
Thermo Fisher Stock Jumps on Second Quarter Results - WFMZ.com
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlig - GuruFocus
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Thermo Fisher Scientific (TMO) Reports Strong Q2 2026 Earnings a - GuruFocus
Thermo Fisher Scientific Inc Stock Price Live, Charts & News - The Economic Times
Thermo Fisher Points to Improving End-Market ActivityThermo Fisher Scientific (NYSE:TMO) - Benzinga
Leerink Partners Adjusts Price Target on Thermo Fisher to $620 From $600, Maintains Outperform Rating - marketscreener.com
Thermo Fisher TMO Stock Draws Bullish Calls Ahead Of Q2 - timothysykes.com
Thermo Fisher Scientific Reports Second Quarter 2026 Results - BioSpace
Thermo Fisher Scientific (NYSE:TMO) Gains Focus In A Selective Market - Kalkine Media
Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today - Yahoo Finance
Thermo Fisher Q2 revenue rises 10% to $11.99 billion - grafa.com
Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 9.89% on Jul 23: A Full Analysis - TradingKey
Thermo Fisher Stock Draws Bullish Targets Ahead Of Q2 - StocksToTrade
Thermo Fisher Scientific Inc (TMO) Stock Forecasts - Yahoo Finance
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $615 From $570 - marketscreener.com
Thermo Fisher Stock Climbs As Analysts Hike Targets Ahead Q2 - timothysykes.com
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):